eli lilly boehringer ingelheim published study claiming duloxetine cymbalta effective treatment pain depressed patients nothing new run several studies results published journal clinical psychiatry november three wise readers jay griffith joseph hasley daniel severn noted serious issues study submitted letter editor published june issue noted patients unclearly described kind pain experiencing study also noted patients taking pain relieving medications six months prior start study least regular basis term defined paper patients experience serious pain take analgesic medication least somewhat regularly finally importantly difference cymbalta placebo statistically significant importantly ignored study authors difference small point rating scale average difference pain ratings favored cymbalta less point griffith colleagues note accurately small advantage cymbalta robust standpoint clinical practice i always glad see readers medical journals willing take time pen good letter editor massive inadequacies study noted going evidence based medicine might want make sure evidence somewhat palatable quality eh kicker lead author cymbalta study stephan brecht boehringer ingelheim opted offer response griffith et al letter i suppose brecht conceding patient population poorly defined cymbalta advantage placebo meager kinda runs counter conclusions study claimed part duloxetine effective painkiller big surprise given prior analysis also cried foul cymbalta claim successfully treat pain depression yet cymbalta continues fly pharmacy shelves physicians really poorly trained understanding scientific literature gee ads say depression hurts rep handed me journal reprints prove painkiller i writing cymbalta scripts like tomorrow failing note cymbalta effects placebo small refusing reply concerns study i hereby nominate authors november cymbalta study especially lead author golden goblet award dedication obfuscation notable keep bad work